Related references
Note: Only part of the references are listed.Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis
Daichi Fujimoto et al.
CLINICAL & EXPERIMENTAL METASTASIS (2014)
Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer
B. Solomon et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
EGFR mutated non-small cell lung cancer patients: More prone to development of bone and brain metastases?
L. E. L. Hendriks et al.
LUNG CANCER (2014)
The Impact of EGFR Mutation Status on Outcomes in Patients With Resected Stage I Non-Small Cell Lung Cancers
Benjamin Izar et al.
ANNALS OF THORACIC SURGERY (2013)
Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas
Melissa L. Johnson et al.
CANCER (2013)
A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non-Small Cell Lung Cancer
Kimberly L. Johung et al.
CLINICAL CANCER RESEARCH (2013)
Determinants of Survival in Advanced Non-Small-Cell Lung Cancer in the Era of Targeted Therapies
Joshua Bauml et al.
CLINICAL LUNG CANCER (2013)
KRAS Mutation: Should We Test for It, and Does It Matter?
Patrick J. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
Chee Khoon Lee et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer
June Koo Lee et al.
CANCER (2012)
Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer
Robert C. Doebele et al.
CANCER (2012)
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Metastatic to the Brain
Mariam Jamal-Hanjani et al.
CLINICAL CANCER RESEARCH (2012)
EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer
Marco Bartolotti et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
Paul W. Sperduto et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR
Shang-Gin Wu et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Adenocarcinoma of the lung with miliary brain and pulmonary metastases with echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase translocation treated with crizotinib: A case report
Alexander T. Falk et al.
LUNG CANCER (2012)
EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases
Hsin-Lun Lee et al.
RADIATION ONCOLOGY (2012)
Effective Use of Thalidomide in the Treatment of Recurrent Metastatic Chordoma
Wen Yee Chay et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer
Wolfram Brugger et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation in the Epidermal Growth Factor Receptor
Britta Weber et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
Alice T. Shaw et al.
LANCET ONCOLOGY (2011)
Evidence-Based Guidelines for the Management of Brain Metastases
Sandeep S. Bhangoo et al.
NEUROSURGERY CLINICS OF NORTH AMERICA (2011)
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
Dora Dias-Santagata et al.
EMBO MOLECULAR MEDICINE (2010)
EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer
April F. Eichler et al.
NEURO-ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A new prognostic index and comparison to three other indices for patients with brain metastases: An analysis of 1,960 patients in the RTOG database
Paul W. Sperduto et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond
Marc Ladanyi et al.
MODERN PATHOLOGY (2008)
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents:: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
Helena Linardou et al.
LANCET ONCOLOGY (2008)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
DA Eberhard et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system
JS Barnholtz-Sloan et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases
MP Mehta et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
